Celltrion

Celltrion is a South Korean biopharmaceutical company that specializes in the research, development, manufacturing, and sale of biosimilars and innovative therapeutics. The company's portfolio covers areas like immunology, oncology, and hematology. While its primary business is biopharmaceuticals, Celltrion also engages in strategic investments in other biotech companies and has co-launched venture funds to foster growth in the healthcare sector. For example, it became the largest shareholder in Iksuda Therapeutics, a UK-based ADC developer, through direct investment and a joint fund with Mirae Asset Group.